Archil Jaliashvili: The Real Battle Is Not About Blood Volume — It Is About Oxygen
Archil Jaliashvili, Co-owner, General Manager of SkinAI, Co-Chief Executive Officer at GeoBio Pharm, shared BHOC – Biological Hemoglobin Oxygen Carrier’s post on LinkedIn:
”The problem is not staying – it is escalating.
Blood and plasma shortages are not just persisting; they are deepening by the day.
And now, new forces are piling on:
- new pandemics,
- wars and conflicts,
- natural disasters,
- logistical breakdowns,
- soaring costs,
- emerging viruses,
- and ever more demanding tests.
- cold chain problem
These are not isolated hurdles – they are a new reality that demands a new understanding.
What is that understanding?
It is this: we must rethink what blood truly is – what we are actually doing, and what we truly need.
Today we state this clearly:
We are not talking about a ‘blood substitute’.
That is the old language.
We are talking about an Precise Oxygenation Therapeutics – to support one of the many critical functions of blood.
BUT – as clear it is main , fundamental function for life, healing, functioning
And here is the key insight:
It is not only about whether blood is available or not.
Even when blood is present – even when supplies are adequate – the blood as an organ still needs support.
We must increase its oxygen-delivery capacity – not just in cases of massive blood loss , hemoglobin level or repeated transfusions, but as a proactive measure to meet the oxygen demands of every patient in crisis.
Because the real battle is not about volume – it is about oxygen.
And that changes everything.”
BHOC – Biological Hemoglobin Oxygen Carrier shared a post on LinkedIn:
”This BBC News article from April 11, 2001, reports that South Africa became the first country in the world to approve a human blood substitute for use in transfusions .
25 years ago, the world already recognized that oxygen delivery does not necessarily have to depend on donor blood.
Dr. Luc Noel was the Coordinator for Blood Transfusion Safety at the WHO in Geneva. He was quoted as saying, “If there is any alternative that is safer than the potential risks of transfusions, then it should be used”
Other posts featuring Archil Jaliashvili on Hemostasis Today.
-
Aug 22, 2026, 09:33Mary Cushman: What Causes PE to Happen in People with DVT?
-
Aug 22, 2026, 07:45Ziad Hijazi: Refining Risk Assessment in Atrial Fibrillation Without Oral Anticoagulation
-
Aug 21, 2026, 21:58Toby Richards: WEHI Trial Solidifies IV Iron as Third-Trimester Standard
-
Aug 21, 2026, 21:51Mehak Trehan: From Reading the Chapter to Writing One
-
Aug 21, 2026, 21:38Ann Reilly: Navigating Postoperative vs. Acute Blood Loss Anemia – A CDI Case Study
-
Aug 21, 2026, 21:29Merlin Crossley: Atomic Precision in Sickle Cell Care – Structural Targeting for Fetal Globin Reactivation
-
Aug 21, 2026, 19:09Aphisit Thongthaisin: Admitted to Sorbonne University’s T2H University Diploma for 2026/2027
-
Aug 21, 2026, 19:07José Luis Ferreiro Gutiérrez: Proud to Be Elected Chairperson-Elect of the ESC Working Group on Thrombosis
-
Aug 21, 2026, 19:00Manuel Monreal: New RIETE Registry Data on VTE Recurrence and Bleeding During Anticoagulation